U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07491523) titled 'Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD' on March 11.
Brief Summary: Patients with ssc-ild receiving double immunosuppression with or without anti fibrotic tratment
Study Start Date: June 01, 2025
Study Type: OBSERVATIONAL
Condition:
SSc-Systemic Sclerosis
Intervention:
DRUG: Antifibrotic drugs (nidanib or pirfenidone)
Ssc - ild
DRUG: MMF Immunosuppression
we will compare patients with SSc-ILD taking RTX and mmf and patients that are taking RTX,mmf and nintedanib
Recruitment Status: RECRUITING
Sponsor: University of Patras
Information provided by (Responsible Party): Liossis Stamatis Ni...